Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30302
Title: Regulatory peptides and systems biology: A new era of translational and reverse-translational neuroendocrinology.
Austin Authors: Eiden, Lee E;Gundlach, Andrew L;Grinevich, Valery;Lee, Mary R;Mecawi, André S;Chen, Duan;Buijs, Ruud M;Hernandez, Vito S;Fajardo-Dolci, Germán;Zhang, Limei
Affiliation: The Florey Institute of Neuroscience and Mental Health
Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, University Heidelberg, Mannheim, Germany..
Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIAAA and NIDA, NIH, Bethesda, MD, USA..
Laboratory of Neuroendocrinology, Department of Biophysics, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil..
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway..
Department of Cell Biology and Physiology, Institute for Biomedical Research, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico..
Department of Physiology, School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico..
School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico..
Department of Physiology, School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico..
Section on Molecular Neuroscience, National Institute of Mental Heath-Intramural Research Program, NIH, Bethesda, MD, USA..
Issue Date: May-2020
Date: 2020-04-19
Publication information: Journal of neuroendocrinology 2020; 32(5): e12844
Abstract: Recently, there has been a resurgence in regulatory peptide science as a result of three converging trends. The first is the increasing population of the drug pipeline with peptide-based therapeutics, mainly in, but not restricted to, incretin-like molecules for treatment of metabolic disorders such as diabetes. The second is the development of genetic and optogenetic tools enabling new insights into how peptides actually function within brain and peripheral circuits to accomplish homeostatic and allostatic regulation. The third is the explosion in defined structures of the G-protein coupled receptors to which most regulatory peptides bind and exert their actions. These trends have closely wedded basic systems biology to drug discovery and development, creating a "two-way street" on which translational advances travel from basic research to the clinic, and, equally importantly, "reverse-translational" information is gathered, about the molecular, cellular and circuit-level mechanisms of action of regulatory peptides, comprising information required for the fine-tuning of drug development through testing in animal models. This review focuses on a small group of 'influential' peptides, including oxytocin, vasopressin, pituitary adenylate cyclase-activating polypeptide, ghrelin, relaxin-3 and glucagon-like peptide-1, and how basic discoveries and their application to therapeutics have intertwined over the past decade.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30302
DOI: 10.1111/jne.12844
ORCID: 0000-0001-7524-944X
0000-0002-6066-9692
0000-0002-6337-8866
0000-0002-2235-0816
0000-0003-4517-6221
0000-0003-3429-4580
0000-0003-3894-4632
0000-0002-1486-1659
0000-0001-6773-7582
0000-0002-7422-5136
Journal: Journal of neuroendocrinology
PubMed URL: 32307768
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/32307768/
Type: Journal Article
Subjects: neuroendocrinology
regulatory peptide
therapeutics
translation
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Dec 5, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.